Head to Head Review: Avalon GloboCare (NASDAQ:ALBT) and Vaxcyte (NASDAQ:PCVX)

Avalon GloboCare (NASDAQ:ALBT) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares Avalon GloboCare and Vaxcyte’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26 million	2.69	-$11.93 million	($1.57)	-0.19
Vaxcyte	N/A	N/A	-$402.27 million	($4.13)	-14.73

Avalon GloboCare has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 64.0% of Avalon GloboCare shares are owned by insiders. Comparatively, 3.6% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Avalon GloboCare and Vaxcyte, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	0	0	0	0	N/A
Vaxcyte	0	0	4	0	3.00

Vaxcyte has a consensus target price of $78.50, suggesting a potential upside of 29.05%. Given Vaxcyte’s higher probable upside, analysts plainly believe Vaxcyte is more favorable than Avalon GloboCare.

Risk and Volatility

Avalon GloboCare has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Profitability

This table compares Avalon GloboCare and Vaxcyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	-750.41%	N/A	-33.18%
Vaxcyte	N/A	-32.04%	-29.72%

Summary

Vaxcyte beats Avalon GloboCare on 6 of the 11 factors compared between the two stocks.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

About Vaxcyte

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.